 The target population of the study includes all patients with paroxysmal atrial fibrillation referred for PVI. After the ablation procedure, patients will be randomized to receive or not receive antiarrhythmic drugs for a period of 6 weeks. Arrhythmia occurrence during this period will be monitored via twice daily transtelephonic monitoring. Clinical visits including a physical exam and 12 lead ECG recording will be scheduled at 6 weeks. The primary endpoint of the study will be a composite endpoint including 1 atrial arrhythmias persisting 24 hours or requiring initiation of antiarrhythmic therapy 2 need for cardioversionhospital admission 3 need for repeat ablation or 4 adverse outcomeintolerance of antiarrhythmic agent requiring drug cessation or change during the 6 week follow up period. 